Biosynth Acquires Fitzgerald Industries Life Sciences Supply Business from Trinity Biotech for $30M

Kohlberg & Company Recapitalizes Trinity Life Sciences

November 30, 2021

Healthcare Services

Kohlberg & Company will recapitalize Trinity Life Sciences, replacing Parthenon Capital as the company’s capital partner. The transaction provides Trinity with new growth capital to support global expansion, technology and data-driven capability investments while Trinity’s management team, led by CEO David Fitzhenry, will remain in place.

KKR-backed Biosynth Carbosynth Acquires vivitide; Ampersand Rolls Over Stake

March 17, 2022

Biotechnology

KKR has invested in Biosynth Carbosynth through its Health Care Strategic Growth Fund II, and Biosynth Carbosynth has acquired vivitide, a global provider of custom peptides and antibody services. Existing owner Ampersand Capital Partners rolled over its entire stake and will be a substantial minority shareholder in the combined global life‑sciences reagents and custom synthesis platform to accelerate geographic expansion, broaden capabilities, and expand the product portfolio.

Trinity Life Sciences Acquires BluePrint Research Group

December 8, 2020

Healthcare Services

Trinity Life Sciences acquired New Jersey-based BluePrint Research Group to strengthen its commercial strategy, insights and analytics capabilities for the life sciences industry and expand its international footprint, including a London office. The deal integrates BluePrint's team into Trinity's global platform and adds resources across India and the U.S. coasts.

Trinity Life Sciences Acquires CBPartners

October 7, 2021

Healthcare Services

Trinity Life Sciences has acquired New York–headquartered CBPartners to significantly scale its Value, Access and Pricing business, adding over 75 dedicated experts and expanding Trinity's presence in New York City, San Francisco and London. The acquisition augments Trinity's market access, pricing and commercial strategy capabilities to better support life sciences companies in bringing products to market and ensuring patient access globally.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

Biosynth Carbosynth Acquires Pepscan

July 4, 2022

Biotechnology

Biosynth Carbosynth, a KKR- and Ampersand-backed supplier of materials to the life-sciences industry, has acquired Pepscan, a Netherlands-based peptide discovery, optimization and GMP peptide manufacturing specialist. The deal adds Pepscan’s proprietary CLIPS technology and epitope-mapping capabilities to Biosynth’s peptide capabilities (including vivitide) to form a new global Peptide division serving pharma, biotech, diagnostics and cosmetics customers.